L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 21, Issue 6, 2007, Pages 445-448

  Xue, Yu Zeng ^a   Wang, Le Xin ^b   Liu, Hua Zhi ^a   Qi, Xue Wen ^a   Wang, Xiao Hua ^a   Ren, Hai Zhou ^a  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

L carnitine; Mortality; Myocardial infarction; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARNITINE; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN I;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THORAX PAIN; VOMITING;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARNITINE; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TROPONIN I;

EID: 36849033861     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6056-9     Document Type: Article

References (16)

1. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997;40:265-86.
2. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2004;1033:79-91.
3. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, et al. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995;26:380-7.
4. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. New Engl J Med 2007;356:1503-16.
5. Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, et al. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. Eur Heart J 2005;26:128-36.
6. Levine GN, Lincoff AM, Ferguson JJ 3rd, Mahaffey KW, Goodman SG, Cannon CP, et al. Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Inte 2005;66:149-57.
7. Liistro F, Angioli P, Falsini G, Ducci K, Baldassarre S, Burali A, et al. Early invasive strategy in elderly patients with non-ST elevation acute coronary syndrome: comparison with younger patients regarding 30 day and long term outcome. Heart 2005; 91:1284-8.
8. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. New Engl J Med 2001;344:1879-87.
9. Lagerqvist B, Husted S, Kontny F, Naslund U, Stahle E, Swahn E, et al. Fast Revascularization during InStability in Coronary artery disease-II Investigators. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 2002;40:1902-14.
10. Levitsky S. Protecting the myocardial cell during coronary revascularization. Circulation 2006;114(1 Suppl):I339-43.
11. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-9.
12. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005;112:1284-8.
13. Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J 2000;139:S124-30.
14. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with l-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006;106:215-23.
15. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of l-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996;72:45-50.
16. Cui J, Das DK, Bertelli A, Tosaki A. Effects of l-carnitine and its derivatives on postis chemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardio myocyte death in isolated rat hearts. Mol Cell Biochem 2003;254:227-34.